oru.sePublications
Change search
Link to record
Permanent link

Direct link
BETA
Andrén, Ove
Alternative names
Publications (10 of 91) Show all publications
Ugge, H., Downer, M. K., Carlsson, J., Bowden, M., Davidsson, S., Mucci, L. A., . . . Andrén, O. (2019). Circulating inflammation markers and prostate cancer. The Prostate, 79(11), 1338-1346
Open this publication in new window or tab >>Circulating inflammation markers and prostate cancer
Show others...
2019 (English)In: The Prostate, ISSN 0270-4137, E-ISSN 1097-0045, Vol. 79, no 11, p. 1338-1346Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Chronic inflammation is thought to influence the risk of prostate cancer. The purpose of this population-based case-control study was to evaluate the association of 48 circulating inflammation markers with prostate cancer, to identify candidate markers for further investigation.

METHODS: Serum samples collected from 235 prostate cancer patients and 198 population-based controls recruited in Örebro County, Sweden, in 1989-1991, were assessed using a multiplex bead-based immunoassay to determine concentrations of 48 circulating inflammation markers. Logistic regression was first used to evaluate the association between individual markers (highest vs lowest concentration quartile) and prostate cancer in unadjusted and mutually adjusted models. Second, patients with inflammatory conditions, metastatic or advanced prostate cancer, were excluded to address the possible influence of systemic disease on inflammation markers.

RESULTS: Individual analyses first identified 21 markers associated with prostate cancer (P < .05), which after mutual adjustment were reduced to seven markers. After the exclusion of men with conditions linked with systemic inflammation, associations between prostate cancer and deviant levels of C-X3-C motif chemokine ligand 1, platelet-derived growth factor subunit B homodimer, interleukin 10, C-C motif chemokine ligand (CCL) 21, and CCL11 remained statistically significant.

CONCLUSIONS: In this explorative study, we identified candidate inflammation markers of possible importance for prostate cancer pathophysiology, for further evaluation in prospective studies.

Place, publisher, year, edition, pages
Alan R. Liss Inc., 2019
Keywords
Circulating, cytokines, inflammation, markers, prostate cancer
National Category
Cancer and Oncology Urology and Nephrology
Identifiers
urn:nbn:se:oru:diva-74753 (URN)10.1002/pros.23842 (DOI)000473235500014 ()31212389 (PubMedID)2-s2.0-85068041866 (Scopus ID)
Note

Funding Agency:

Lions Cancerforskningsfond vid Akademiska sjukhuset i Uppsala. (Part of Lions International)

Available from: 2019-06-20 Created: 2019-06-20 Last updated: 2019-08-09Bibliographically approved
Zelic, R., Zugna, D., Bottai, M., Andrén, O., Fridfeldt, J., Carlsson, J., . . . Akre, O. (2019). Estimation of Relative and Absolute Risks in a Competing-Risks Setting Using a Nested Case-Control Study Design: Example From the ProMort Study. American Journal of Epidemiology, 188(6), 1165-1173
Open this publication in new window or tab >>Estimation of Relative and Absolute Risks in a Competing-Risks Setting Using a Nested Case-Control Study Design: Example From the ProMort Study
Show others...
2019 (English)In: American Journal of Epidemiology, ISSN 0002-9262, E-ISSN 1476-6256, Vol. 188, no 6, p. 1165-1173Article in journal (Refereed) Published
Abstract [en]

In this paper, we describe the Prognostic Factors for Mortality in Prostate Cancer (ProMort) study and use it to demonstrate how the weighted likelihood method can be used in nested case-control studies to estimate both relative and absolute risks in the competing-risks setting. ProMort is a case-control study nested within the National Prostate Cancer Register (NPCR) of Sweden, comprising 1,710 men diagnosed with low- or intermediate-risk prostate cancer between 1998 and 2011 who died from prostate cancer (cases) and 1,710 matched controls. Cause-specific hazard ratios and cumulative incidence functions (CIFs) for prostate cancer death were estimated in ProMort using weighted flexible parametric models and compared with the corresponding estimates from the NPCR cohort. We further drew 1,500 random nested case-control subsamples of the NPCR cohort and quantified the bias in the hazard ratio and CIF estimates. Finally, we compared the ProMort estimates with those obtained by augmenting competing-risks cases and by augmenting both competing-risks cases and controls. The hazard ratios for prostate cancer death estimated in ProMort were comparable to those in the NPCR. The hazard ratios for dying from other causes were biased, which introduced bias in the CIFs estimated in the competing-risks setting. When augmenting both competing-risks cases and controls, the bias was reduced.

Place, publisher, year, edition, pages
Oxford University Press, 2019
Keywords
absolute risk, competing risks, cumulative incidence function, flexible parametric survival model, inverse probability weighting, nested case-control studies, weighted likelihood
National Category
Cancer and Oncology Urology and Nephrology
Identifiers
urn:nbn:se:oru:diva-75236 (URN)10.1093/aje/kwz026 (DOI)000473760200020 ()30976789 (PubMedID)2-s2.0-85067089473 (Scopus ID)
Funder
Swedish Cancer Society
Available from: 2019-07-25 Created: 2019-07-25 Last updated: 2019-07-25Bibliographically approved
Chetta, P., Zadra, G., Cangi, M. G., Francaviglia, I., Luciano, R., Davidsson, S., . . . Loda, M. (2019). IDH1 Mutations Mark a High-Grade, Potentially Aggressive Variant of Prostate Cancer. Paper presented at 108th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) - Unlocking Your Ingenuity, National Harbor, MD, USA, March 16-21, 2019. Laboratory Investigation, 32(Suppl. 2)
Open this publication in new window or tab >>IDH1 Mutations Mark a High-Grade, Potentially Aggressive Variant of Prostate Cancer
Show others...
2019 (English)In: Laboratory Investigation, ISSN 0023-6837, E-ISSN 1530-0307, Vol. 32, no Suppl. 2Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
Nature Publishing Group, 2019
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:oru:diva-75864 (URN)000478081101280 ()
Conference
108th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) - Unlocking Your Ingenuity, National Harbor, MD, USA, March 16-21, 2019
Available from: 2019-08-23 Created: 2019-08-23 Last updated: 2019-08-23Bibliographically approved
Erlandsson, A., Carlsson, J., Lundholm, M., Fält, A., Andersson, S.-O., Andrén, O. & Davidsson, S. (2019). M2 macrophages and regulatory T cells in lethal prostate cancer. The Prostate, 79(4), 363-369
Open this publication in new window or tab >>M2 macrophages and regulatory T cells in lethal prostate cancer
Show others...
2019 (English)In: The Prostate, ISSN 0270-4137, E-ISSN 1097-0045, Vol. 79, no 4, p. 363-369Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Prostate cancer (PCa) is one of the most frequently diagnosed cancers in the world. Emerging evidence suggests that inflammatory cells such as M2 macrophages and regulatory T cells (Tregs) can contribute to cancer progression by suppressing the anti‐tumor immune response. This study investigated the number of CD163‐positive M2 macrophages in PCa tissue. It also investigated the correlation and interaction of M2 macrophages and Tregs.

METHODS: were assessed using Spearman's rank-order correlation and a likelihood test, respectively. Logistic regression was used to estimate odds ratios (ORs) for lethal PCa and macrophage counts.

RESULTS: showed a significant correlation (P < 0.001) but no interactions. The OR for lethal PCa was 1.93 (95%CI: 1.23-3.03) for men with high numbers of M2 macrophages. Also for cases with uncertain outcome (GS categories 3 + 4 and 4 + 3) high numbers of M2 macrophages does predict a poorer prognosis.

CONCLUSIONS: Our data showed that men with high numbers of M2 macrophages in the prostate tumor environment had increased odds of dying of PCa. It is possible that M2 macrophages, together with other suppressor cells such as Tregs , promote an immunosuppressive environment.

Place, publisher, year, edition, pages
John Wiley & Sons, 2019
Keywords
CD163, FOXP3, TAMs, Tregs
National Category
Urology and Nephrology Cancer and Oncology
Identifiers
urn:nbn:se:oru:diva-70404 (URN)10.1002/pros.23742 (DOI)000456214000004 ()30500076 (PubMedID)2-s2.0-85057833977 (Scopus ID)
Available from: 2018-12-03 Created: 2018-12-03 Last updated: 2019-02-05Bibliographically approved
Jerlström, T., Ruoqing, C., Liedberg, F., Andrén, O., Ströck, V., Aljabery, F. A. S., . . . Fall, K. (2019). No increased risk of short-term complications after radical cystectomy for muscle-invasive bladder cancer among patients treated with preoperative chemotherapy: a nation-wide register-based study. World journal of urology
Open this publication in new window or tab >>No increased risk of short-term complications after radical cystectomy for muscle-invasive bladder cancer among patients treated with preoperative chemotherapy: a nation-wide register-based study
Show others...
2019 (English)In: World journal of urology, ISSN 0724-4983, E-ISSN 1433-8726Article in journal (Refereed) Epub ahead of print
Abstract [en]

PURPOSE: Preoperative chemotherapy is underused in conjunction with radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) due to concerns for complications and delay of surgery. Prospective data on short-term complications from population-based settings with frequent use of preoperative chemotherapy and standardised reporting of complications is lacking.

METHODS: We identified 1,340 patients who underwent RC between 2011 and 2015 in Sweden due to MIBC according to the Swedish Cystectomy Register. These individuals were followed through linkages to several national registers. Propensity score adjusted logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for complications and death within 90 days of surgery, comparing patients receiving preoperative chemotherapy or not.

RESULTS: Minimum two cycles of preoperative chemotherapy were given to 519 (39%) of the patients, who on average tended to be younger, have higher education, better physical status, and more advanced bladder cancer than patients not receiving chemotherapy. After adjusting for these and other parameters, there was no association between treatment with preoperative chemotherapy and short-term complications (OR 1.06 95% CI 0.82-1.39) or mortality (OR 0.75 95% CI 0.36-1.55). We observed a risk reduction for gastrointestinal complications among patients who received preoperative chemotherapy compared with those who did not (OR 0.49 95% CI 0.30-0.81).

CONCLUSION: This nation-wide population-based observational study does not suggest that preoperative chemotherapy, in a setting with high utilisation of such treatment, is associated with an increased risk of short-term complications in MIBC patients treated with radical cystectomy.

Place, publisher, year, edition, pages
Springer, 2019
Keywords
Bladder cancer, Induction chemotherapy, Neoadjuvant chemotherapy, Postoperative complications, Radical cystectomy
National Category
Cancer and Oncology Urology and Nephrology
Identifiers
urn:nbn:se:oru:diva-73968 (URN)10.1007/s00345-019-02770-2 (DOI)31020424 (PubMedID)
Available from: 2019-04-29 Created: 2019-04-29 Last updated: 2019-04-29Bibliographically approved
Davidsson, S., Carlsson, J., Giunchi, F., Harlow, A., Kirrander, P., Rider, J., . . . Andrén, O. (2019). PD-L1 Expression in Men with Penile Cancer and its Association with Clinical Outcomes. European Urology Oncology, 2(2), 214-221
Open this publication in new window or tab >>PD-L1 Expression in Men with Penile Cancer and its Association with Clinical Outcomes
Show others...
2019 (English)In: European Urology Oncology, E-ISSN 2588-9311, Vol. 2, no 2, p. 214-221Article in journal (Refereed) Published
Abstract [en]

Background: It has been hypothesized that PD-L1 expression in tumor cells and tumor-infiltrating immune (TII) cells may contribute to tumor progression by inhibiting antitumor immunity.

Objective: To investigate the association between PD-L1 expression in tumor cells and TII cells and clinical outcomes in penile cancer.

Design, setting, and participants: A cohort of 222 men treated for penile squamous cell carcinoma (SqCC) at Örebro University Hospital between 1984 and 2008 with long-term follow-up (median 34 mo) was evaluated for PD-L1 expression in tumor cells and TII cells via immunohistochemistry.

Outcome measurements and statistical analysis: Association between clinicopathological features and PD-L1 expression was estimated using χ2 and Fisher's exact tests. For survival analyses, Kaplan-Meier curves with log-rank tests and multivariate Cox proportional hazards regression models were used.

Results and limitations: We found that 32.1% of the tumors and 64.2% of the TII cells expressed PD-L1. Our data demonstrate that penile SqCC patients with PD-L1–positive tumor cells or TII cells are at significant risk of lower cancer-specific survival and that the prognostic value of PD-L1 expression was strongest for tumor cell positivity. The use of tissue microarrays rather than whole sections may be viewed as a limitation.

Conclusions: Tumor PD-L1 expression independently identifies penile SqCC patients at risk of poor clinical outcomes.

Patient summary: We investigated how many patients with penile cancer had tumors that manufactured PD-L1, a protein that decreases the ability of the immune system to fight cancer. We found that up to one-third of penile tumors make this protein. Patients whose tumors make PD-L1 have more aggressive penile cancer and worse clinical outcomes.

Place, publisher, year, edition, pages
Elsevier, 2019
Keywords
Penile squamos cell carcinoma, Immunohistochemistry, PD-L1
National Category
Urology and Nephrology Cancer and Oncology
Identifiers
urn:nbn:se:oru:diva-73687 (URN)10.1016/j.euo.2018.07.010 (DOI)000474610700014 ()31017099 (PubMedID)2-s2.0-85065334391 (Scopus ID)
Available from: 2019-04-12 Created: 2019-04-12 Last updated: 2019-07-29Bibliographically approved
Offermann, A., Roth, D., Hupe, M. C., Hohensteiner, S., Becker, F., Joerg, V., . . . Perner, S. (2019). TRIM24 as an independent prognostic biomarker for prostate cancer. Urologic Oncology, 37(9), Article ID 576.e1.
Open this publication in new window or tab >>TRIM24 as an independent prognostic biomarker for prostate cancer
Show others...
2019 (English)In: Urologic Oncology, ISSN 1078-1439, E-ISSN 1873-2496, Vol. 37, no 9, article id 576.e1Article in journal (Refereed) Published
Abstract [en]

Introduction: Simply applicable biomarkers for prostate cancer patients predicting the clinical course are urgently needed. Recently, TRIM24 has been identified to promote androgen receptor signaling and to correlate with an aggressive prostate cancer phenotype. Based on these data, we proofed TRIM24 as a prognostic biomarker for risk stratification.

Materials and Methods: We performed TRIM24 immunohistochemistry on 2 independent cohorts including a total of 806 primary tumors, 26 locally advanced/recurrent tumors, 30 lymph node metastases, 30 distant metastases, and 129 benign prostatic samples from 497 patients as well as on 246 prostate needle biopsies. Expression data were correlated with clinic-pathological data including biochemical recurrence-free survival (bRFS) as endpoint.

Results: Benign samples show no or low TRIM24 expression in 94%, while tumor tissues demonstrate significant higher levels. Strongest expression is observed in advanced and metastatic tumors. In multivariate analyses, TRIM24 up-regulation on radical prostatectomy specimens correlates with shorter bRFS independent of other prognostic parameters. 5-(10-) year bRFS rates for TRIM24 negative, low, medium and high expressing tumors are 93.1(93.1)%, 75.4(68.5)%, 54.9(47.5)% and 43.1(32.3)%, respectively. Of interest, tumors diagnosed as indolent disease, TRIM24 expression stratifies patients into specific risk groups. Increased TRIM24 expression associates with higher grade group, positive nodal status and extraprostatic tumor growth. TRIM24 assessment on prostate needle biopsies taken prior to treatment decision at time of initial diagnosis significantly correlates with recurrence after surgery.

Conclusion: Using 2 large independent radical prostatectomy specimen cohorts, we found that TRIM24 expression predicts patients' risk to develop disease recurrence with high accuracy and independent from other established biomarkers. Further, this is the first study exploring TRIM24 expression on prostate needle biopsies which represents the clinically relevant tissue type on which biomarkers guide treatment decisions. Thus, we strongly suggest introducing TRIM24 evaluation in prostate needle biopsies in clinical routine as an inexpensive and simple immunohistochemical test.

Place, publisher, year, edition, pages
Elsevier, 2019
Keywords
Prostate cancer, TRIM24, Biomarker, Disease recurrence, Immunohistochemical test
National Category
Urology and Nephrology Cancer and Oncology
Identifiers
urn:nbn:se:oru:diva-76050 (URN)10.1016/j.urolonc.2019.05.006 (DOI)000481583800016 ()31178279 (PubMedID)2-s2.0-85066785386 (Scopus ID)
Note

Funding Agencies:

German Research Foundation  DFG PE1179/9-1  PE1179/11-1 

University of Luebeck 

Available from: 2019-09-05 Created: 2019-09-05 Last updated: 2019-09-05Bibliographically approved
Ugge, H., Udumyan, R., Carlsson, J., Andrén, O., Montgomery, S., Davidsson, S. & Fall, K. (2018). Acne in late adolescence and risk of prostate cancer. International Journal of Cancer, 1580-1585
Open this publication in new window or tab >>Acne in late adolescence and risk of prostate cancer
Show others...
2018 (English)In: International Journal of Cancer, ISSN 0020-7136, E-ISSN 1097-0215, p. 1580-1585Article in journal (Refereed) Published
Abstract [en]

Accumulating evidence suggest that Propionibacterium acnes may play a role in prostate carcinogenesis, but data are so far limited and inconclusive. The aim of this population-based cohort study was therefore to test whether presence of acne vulgaris during late adolescence is associated with an increased risk of prostate cancer later in life. We identified a large cohort of young men born in Sweden between 1952 and 1956, who underwent mandatory assessment for military conscription around the age of 18 (n= 243,187). Test information along with health data including medical diagnoses at time of conscription was available through the Swedish Military Conscription Register and the National Patient Register. The cohort was followed through linkages to the Swedish Cancer Register to identify the occurrence of prostate cancer until December 31st 2009. We used Cox regression to calculate adjusted hazard ratios (HR) and 95% confidence intervals (95% CI) for the association between acne in adolescence and prostate cancer risk. A total of 1,633 men were diagnosed with prostate cancer during a median follow-up of 36.7 years. A diagnosis of acne was associated with a statistically significant increased risk for prostate cancer (adjusted HR: 1.43 95%; CI: 1.06-1.92), particularly for advanced stage disease (HR: 2.37 95%; CI 1.19-4.73). A diagnosis of acne classified as severe conferred a 6-fold increased risk of prostate cancer (HR: 5.70 95% CI 1.42-22.85). Data from this large prospective population-based cohort add new evidence supporting a role of P acnes infection in prostate cancer.

Place, publisher, year, edition, pages
Hoboken, NJ, USA: John Wiley & Sons, 2018
Keywords
Propionibacterium acnes; prostate cancer; acne vulgaris; inflammation; acne vulgaris
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:oru:diva-63302 (URN)10.1002/ijc.31192 (DOI)000425184800009 ()29205339 (PubMedID)2-s2.0-85037982996 (Scopus ID)
Note

Funding Agency:

UK Economic and Social Research Council (ESRC)  RES-596-28-0001  ES/JO19119/1

Available from: 2017-12-11 Created: 2017-12-11 Last updated: 2019-04-09Bibliographically approved
Ugge, H., Udumyan, R., Carlsson, J., Davidsson, S., Andrén, O., Montgomery, S. & Fall, K. (2018). Appendicitis before age 20 years is associated with an increased risk of later prostate cancer. Cancer Epidemiology, Biomarkers and Prevention, 27(6), 660-664
Open this publication in new window or tab >>Appendicitis before age 20 years is associated with an increased risk of later prostate cancer
Show others...
2018 (English)In: Cancer Epidemiology, Biomarkers and Prevention, ISSN 1055-9965, E-ISSN 1538-7755, Vol. 27, no 6, p. 660-664Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Appendicitis before age 20 years has been observed to influence the risk of several inflammatory conditions, possibly through underlying immunological mechanisms. Inflammation has further been suggested to be involved in prostate cancer development. We therefore hypothesized that immunological characteristics signaled by appendicitis before late adolescence might influence the risk of later prostate cancer, and aimed to evaluate this association in a population-based study.

METHODS: We identified a large cohort of Swedish men who underwent assessment for military conscription around the age of 18 years (n= 242,573). Medical diagnoses at time of conscription were available through the Swedish Military Conscription Register. The Swedish Cancer Register was used to identify diagnoses of prostate cancer. Multivariable adjusted Cox regression analyses were used to estimate hazard ratios (HR) and 95% confidence intervals (95% CI) for the association between appendicitis and prostate cancer.

RESULTS: During a median of 36.7 years of follow-up, 1,684 diagnoses of prostate cancer occurred. We found a statistically significant association between appendicitis and overall prostate cancer (adjusted HR: 1.70; 95% CI: 1.08-2.67). The risk was notably increased for advanced (HR: 4.42; 95% CI: 1.74-11.22) and lethal (HR: 8.95; 95% CI: 2.98-26.91) prostate cancer.

CONCLUSION: These results suggest that a diagnosis of appendicitis before adulthood potentially signals underlying immune characteristics and a pattern of inflammatory response relevant to prostate cancer risk.

IMPACT: The study lends support to the proposed role of inflammation in prostate carcinogenesis, and adds another area of investigation potentially relevant to prostate cancer development.

Place, publisher, year, edition, pages
American Association for Cancer Research, 2018
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:oru:diva-66449 (URN)10.1158/1055-9965.EPI-17-1204 (DOI)000433945800006 ()29588305 (PubMedID)2-s2.0-85047896683 (Scopus ID)
Note

Funding Agency:

UK Economic and Social Research Council (ESRC)  RES-596-28-0001  ES/JO19119/1

Available from: 2018-04-13 Created: 2018-04-13 Last updated: 2019-04-09Bibliographically approved
Davidsson, S., Andrén, O., Ohlson, A.-L., Carlsson, J., Andersson, S.-O., Giunchi, F., . . . Fiorentino, M. (2018). FOXP3+ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer. The Prostate, 78(1), 40-47
Open this publication in new window or tab >>FOXP3+ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer
Show others...
2018 (English)In: The Prostate, ISSN 0270-4137, E-ISSN 1097-0045, Vol. 78, no 1, p. 40-47Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: The tumor promoting or counteracting effects of the immune response to cancer development are thought to be mediated to some extent by the infiltration of regulatory T cells (Tregs ). In the present study we evaluated the prevalence of Treg populations in stromal and epithelial compartments of normal, post atrophic hyperplasia (PAH), prostatic intraepithelial neoplasia (PIN), and tumor lesions in men with and without prostate cancer.

METHODS: Study subjects were 102 men consecutively diagnosed with localized prostate cancer undergoing radical prostatectomy and 38 men diagnosed with bladder cancer undergoing cystoprostatectomy without prostate cancer at the pathological examination. Whole mount sections from all patients were evaluated for the epithelial and stromal expression of CD4+ Tregs and CD8+ Tregs in normal, PAH, PIN, and tumor lesions. A Friedmańs test was used to investigate differences in the mean number of Tregs across histological lesions. Logistic regression was used to estimate crude and adjusted odds ratios (OR) for prostate cancer for each histological area.

RESULTS: In men with prostate cancer, similarly high numbers of stromal CD4+ Tregs were identified in PAH and tumor, but CD4+ Tregs were less common in PIN. Greater numbers of epithelial CD4+ Tregs in normal prostatic tissue were positively associated with both Gleason score and pT-stage. We observed a fourfold increased risk of prostate cancer in men with epithelial CD4+ Tregs in the normal prostatic tissue counterpart.

CONCLUSIONS: Our results may suggest a possible pathway through which PAH develops directly into prostate cancer in the presence of CD4+ Tregs and indicate that transformation of the anti-tumor immune response may be initiated even before the primary tumor is established.

Place, publisher, year, edition, pages
Hoboken, USA: John Wiley & Sons, 2018
Keywords
CD4+FOXP3+ Tregs, Lag-3+ Tregs, prostate carcinoma
National Category
Endocrinology and Diabetes Urology and Nephrology
Identifiers
urn:nbn:se:oru:diva-63016 (URN)10.1002/pros.23442 (DOI)000417131400006 ()29105795 (PubMedID)2-s2.0-85037338544 (Scopus ID)
Note

Funding Agencies:

Foundation for Medical Research at Örebro University Hospital  

Lions Cancer Foundation  

Örebro County Council Research Committee 

Available from: 2017-12-07 Created: 2017-12-07 Last updated: 2018-08-31Bibliographically approved
Organisations

Search in DiVA

Show all publications